Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action

Core Viewpoint - The FDA has postponed its decision on Disc Medicine Inc.'s experimental treatment, bitopertin, for erythropoietic protoporphyria to February 10, raising questions about the drug's efficacy and potential risks [1][2][3]. Group 1: FDA Review Process - The FDA reviewers have delayed their decision on bitopertin by approximately two weeks, now set for February 10 [1]. - Regulators are questioning the reliability of "pain-free time in the sun" as a secondary endpoint for effectiveness, suggesting that biomarker data may be more appropriate for supporting approval [2]. - FDA staff are evaluating whether bitopertin poses any risk of misuse or addiction, adding complexity to the review process [3]. Group 2: Market Reaction and Analyst Insights - Disc Medicine's stock has seen positive movement, with a reported increase of 2.59% to $72.88 at the time of publication [5]. - Analyst Douglas Tsao from H.C. Wainwright expressed confidence in the likelihood of approval despite the ongoing review process, indicating that any potential delay would be modest [5]. - H.C. Wainwright maintains a Buy rating on Disc Medicine with a price target of $118 [5].